Almost £2.8m has been made available to 51 projects in primary care, clinical commissioning groups and trusts across England to help them integrate supported rapid uptake products (RUP) into everyday practice. They include six projects within the Oxford AHSN region totalling more than £300,000.
The RUP programme supports stronger adoption and spread of proven innovations approved by NICE which target clinical priorities set out in the NHS Long Term Plan.
The four 2021/22 supported RUPs are:
- Lipid management, a NICE-endorsed clinical pathway to help reduce cholesterol
- Asthma biologics, a treatment for severe asthma (led by Oxford AHSN)
- FeNO testing, aiding diagnosis of asthma
- Tamoxifen as a preventative treatment for breast cancer
Funding has been made available for the first three RUPs and organisations can apply for funding for Tamoxifen projects until 9 July.
The following projects in the Oxford AHSN region have made successful bids through the Pathway Transformation Fund:
- Lipid management – Bedfordshire, Luton and Milton Keynes CCG
- Asthma biologics – Oxford University Hospitals
- FeNO testing – Banbury Cross Health Centre / Berinsfield Health Centre / Braccan Health Network (Bracknell Forest) / Healthier Oxford Network